Disease Domain | Count |
---|---|
Neoplasms | 4 |
Endocrinology and Metabolic Disease | 2 |
Hemic and Lymphatic Diseases | 1 |
Immune System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 2 |
Bispecific antibody | 1 |
Antibody drug conjugate (ADC) | 1 |
Monoclonal antibody | 1 |
Target |
Mechanism CLDN18.2 inhibitors [+2] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. JP |
First Approval Date26 Mar 2024 |
Target |
Mechanism Tubulin inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date18 Dec 2019 |
Target |
Mechanism AXL inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. JP |
First Approval Date21 Sep 2018 |
Start Date10 Jul 2024 |
Sponsor / Collaborator |
Start Date01 Nov 2023 |
Sponsor / Collaborator |
Start Date17 Jun 2022 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Ipragliflozin L-Proline ( SGLT2 ) | Diabetes Mellitus, Type 2 More | Approved |
Zolbetuximab ( CLDN18.2 ) | CLDN18.2 positive Gastroesophageal junction adenocarcinoma More | Approved |
Enfortumab Vedotin-ejfv ( Tubulin x nectin-4 ) | Locally Advanced Urothelial Carcinoma More | Approved |
Gilteritinib Fumarate ( AXL x FLT3 ) | FLT3 positive Acute Myeloid Leukemia More | Approved |
CLDN4/4-1BB targeted bispecific antibody(Astellas Pharma) ( 4-1BB x CLDN4 ) | Neoplasms More | Preclinical |